



## RÉFÉRENCES

1. Chan B, Young W. Burden of Cardiac Disease. Toronto: Institute for Clinical Evaluative Sciences (ICES); 1999.
2. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. *N Engl J Med* 2000;343(1):16-22.
3. Bondy S, Jaglal S, Slaughter P. Area variation in heart disease mortality rates. Toronto: Institute for Clinical Evaluative Studies (ICES); 1999.
4. Tanuseputro P, Manuel DG, Leung M, Nguyen K, Johansen H. Risk factors for cardiovascular disease in Canada. *Can J Cardiol* 2003;19(11):1249-59.
5. Tableaux de données sur les indicateurs de la santé de Statistique Canada. [http://www.statcan.ca/francais/freepub/82-221-XIF/00604/tables\\_f.htm](http://www.statcan.ca/francais/freepub/82-221-XIF/00604/tables_f.htm).
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. National Cholesterol Education Program; National Heart, Lung, and Blood Institute; National Institutes of Health. Septembre 2002; p. 11-15.
7. Programme éducatif canadien sur l'hypertension (PECH). Recommandations pour la prise en charge et le traitement de l'hypertension 2006. [http://hypertension.ca/chep/fr/wp-content/uploads/2007/10/chep\\_06\\_bookletfulltext\\_vf.pdf](http://hypertension.ca/chep/fr/wp-content/uploads/2007/10/chep_06_bookletfulltext_vf.pdf).
8. Comité d'experts des Lignes directrices de pratique clinique de l'Association canadienne du diabète. Dyslipidémies chez les adultes diabétiques. *Can J Diabetes*. 2006;30(3):230-240. <http://www.diabetes.ca/cpgfrancais/downloads/dyslipidemie.pdf>.
9. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. *Can J Cardiol*. 2006;22(11):913-927. [www.ccs.ca/download/position\\_statements/lipids.pdf](http://www.ccs.ca/download/position_statements/lipids.pdf).
10. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic groups (SHARE). *Lancet*. 2000;356:279-84.
11. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. *JAMA*. 2004;291:2591-9.
12. Anand SS, Yi Q, Gerstein H, et al. Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. *Circulation*. 2003;108:420-5.
13. George K, Alberti MM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. *Lancet*. 2005;1059-1062.
14. Lau DCW, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E pour les membres du Groupe d'experts d'Obésité Canada sur les lignes directrices. Lignes directrices canadiennes de 2006 sur la prise en charge et la prévention de l'obésité chez les adultes et les enfants [sommaire]. *CMAJ*. 2007; 176(8): S1-S14. <http://www.cmaj.ca/cgi/content/full/176/8/SF1>.
15. Programme éducatif canadien sur l'hypertension (PECH). Recommandations pour la prise en charge et le traitement de l'hypertension 2007. <http://www.hypertension.ca/chep/fr/>.
16. Fodor G, Kotrec M, Bacskai K, Dorner T, Lietava J, Sonkodi S, Rieder A, Turton P. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. *Journal of Hypertension*. 2005; 23(6): 1261-1266.
17. Société canadienne de néphrologie (SCN), 2006. Traitement et orientation des patients adultes présentant une diminution de la fonction rénale : Position de la société canadienne de néphrologie. <http://www.csnsn.ca/local/files/CSN%20Position%20Paper%20Sept2006%20French.pdf>.
18. Clinical Tobacco Intervention. Smoking Progress Notes. [www.omacti.org](http://www.omacti.org).
19. Fiore MC, Frohman JG, Van Harrison R, Thomas LA. US public health service clinical practice guideline: Treating tobacco use and dependence. *Respiratory Care*. 2000; 45(10): 1200-1262.
20. Smoking Cessation, Guideline for Clinical Care. University of Michigan Health System. 2006.
21. Rethinking Stop-Smoking Medications: Treatment Myths and Medical Realities. Ontario Medical Association, janvier 2008.
22. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observation on male British doctors. *BMJ*. 2004; 328: 15 -19.



23. PACE Canada. Health Provider's Guide to Counselling for Healthy Active Living. 2000.
24. Warburton DER, Nicol CW, Bredin SSD. Prescribing exercise as preventive therapy. *CMAJ*. 2006; 174(7): 961-974.
25. Jacobson DM, Strohecker L, Compton MT, Katz DL. Physical activity counselling in the adult primary care setting. Position statement of the American College of Preventive Medicine. *Am J Prev Med* 2005; 29(2): 158-162.
26. La Stratégie canadienne de l'AVC. Recommandations canadiennes pour les pratiques optimales de soins de l'AVC 2006. [www.canadianstrokestrategy.ca/fr/outilsressources/pratiques\\_optimales.html](http://www.canadianstrokestrategy.ca/fr/outilsressources/pratiques_optimales.html).
27. Smith S, Allan J, Blair S et al. AHA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National, Heart, Lung, Blood Institute. *Circulation*. 2006; 113;2363-2372. [www.circ.ahajournals.org/cgi/content/full/113/19/2363](http://www.circ.ahajournals.org/cgi/content/full/113/19/2363).
28. Abramson B, Huckell V et al. Canadian Cardiovascular Society Consensus Conference: Peripheral arterial disease. *Can J Cardiol*. 2005; 21(12): 997-1006. [www.canadianguidelines.com/landing.asp?topic=25](http://www.canadianguidelines.com/landing.asp?topic=25).
29. Comité d'experts des Lignes directrices de pratique clinique de l'Association canadienne du diabète. Lignes directrices de pratique clinique 2003 de l'Association canadienne du diabète pour la prévention et le traitement du diabète au Canada. *Can J Diabetes* 2003;27(suppl2): S1-S152. [www.diabetes.ca/cpgfrançais/download.aspx](http://www.diabetes.ca/cpgfrançais/download.aspx).
30. Fondation des maladies du cœur du Canada. « Voici comment mesurer votre tour de taille ». Tiré du site Web de la fondation : <http://www.fmcoeur.com/site/pp.aspx?c=ntJXJ8MMIqE&b=3876259>.
31. Fondation des maladies du cœur du Canada. Manage your blood pressure: If you have trouble remembering your pills. Tiré du site Web de la fondation : [ww2.heartandstroke.ca/images/english/BP\\_Brochure\\_ENG.pdf](http://ww2.heartandstroke.ca/images/english/BP_Brochure_ENG.pdf).
32. Australia Heart Foundation. Getting patients more active: Practical information for general practices (2005). Site consulté le 21 janvier 2008 : [www.heartfoundation.org.au/document/NHF/GP\\_Getting\\_patients\\_more\\_active.pdf](http://www.heartfoundation.org.au/document/NHF/GP_Getting_patients_more_active.pdf).
33. Australian General Practice. Lifescripts: Physical activity: Helping patients to become more active (2004). Site consulté le 21 janvier 2008 : [www.adgp.com.au/site/content.cfm?page\\_id=10004&current\\_category\\_code=1254&leca=226](http://www.adgp.com.au/site/content.cfm?page_id=10004&current_category_code=1254&leca=226).
34. Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: A consensus on Type 2 diabetes prevention. *Diabetic Medicine*, 24, 451-463.